Literature DB >> 33836528

Gastrointestinal Tract Lymphomas.

Jessica Alvarez-Lesmes1, Jennifer R Chapman1, Daniel Cassidy1, Yi Zhou1, Monica Garcia-Buitrago1, Elizabeth A Montgomery1, Izidore S Lossos2,3, Daniel Sussman4, Julio Poveda1.   

Abstract

CONTEXT.—: The gastrointestinal (GI) tract is the most common site of extranodal non-Hodgkin lymphoma, accounting for 20% to 40% of all extranodal lymphomas. The majority of these are systemic processes secondarily involving the GI tract. Primary GI lymphomas are less common, accounting for approximately 10% to 15% of all non-Hodgkin lymphomas. Most non-Hodgkin lymphomas involving the GI tract are of B-cell lineage, of which diffuse large B-cell lymphoma is the most common subtype, irrespective of location. OBJECTIVE.—: To review the lymphoproliferative neoplasms of B-cell and T-cell lineage involving the luminal GI tract according to the most prevalent subtypes at each anatomic site. DATA SOURCE.—: Systematic search of the PubMed database for updated literature on GI lymphoma epidemiology, subtypes, clinical, endoscopic, and genetic findings. Histologic images are derived from our collection of clinical cases. CONCLUSIONS.—: The GI tract is the most common site of extranodal lymphoproliferative neoplasms. Recognition of the most frequently encountered GI lymphomas is imperative for patient management and treatment.

Entities:  

Mesh:

Year:  2021        PMID: 33836528     DOI: 10.5858/arpa.2020-0661-RA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  2 in total

1.  Colo-enteric fistula associated with diffuse large B cell lymphoma that resulted in gastrointestinal bleeding: A case report and literature review.

Authors:  Shih-Wei Chiang; Tzu-Wei Chiang
Journal:  Int J Surg Case Rep       Date:  2022-01-31

Review 2.  Primary small intestinal extranodal NK/T cell lymphoma, nasal type with kidney involvement: a rare case report and literature review.

Authors:  Shuyan Mao; Changying Diao; Lei Cao
Journal:  Diagn Pathol       Date:  2022-10-05       Impact factor: 3.196

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.